Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction, in situ thrombosis, and vascular remodeling of small pulmonary arteries inducing increased pulmonary arterial resistance. Conventional treatment is based on life style modification and nonspecific treatment (warfarine, diuretics, oxygen). Calcium channel blockers are vasodilatators that have been shown to be of great efficacy in a very specific subpopulation of patients with PAH. For the majority of patients, specific PAH therapies are still lacking. Numerous studies evaluating prostacyclin agonists, endothelin-receptor antagonists, and phosphodiesterase type 5 inhibitors are now available to guide therapeutic choices. Despite those important advances there is still no cure for PAH. Fortunately, research is ongoing and many drugs show promises.
Introduction
Pulmonary arterial hypertension (PAH) is a rare disease affecting at least 15 adults per million inhabitants in France . It is characterized by vascular proliferation and remodeling, resulting in progressive increase in pulmonary arterial resistance, right heart failure, and eventually, death. For many years the treatment was extremely limited. The prognosis was devastating, with a mean survival time of 53 years after diagnosis [D'alonzo et al. 1991] . A better understanding of physiopathological mechanisms of the disease allowed the development of several innovative molecules and in the last ten years the management of PAH has become more specific and successful. Nevertheless, there is still, unfortunately, no cure for this disease.
Pulmonary arterial hypertension can be idiopathic (iPAH) or associated with another disease (Table 1) . In either case, the exact etiology of PAH remains unknown. Initially, vasoconstriction was thought to be the main mechanism leading to PAH. It is now recognized that endothelial dysfunction plays an important role in PAH. It is responsible for vascular tonicity imbalance, increased smooth muscle proliferation and hypertrophy and vascular remodeling, all key elements in this disease [Laurent et al. 1996 ]. Natural endothelial vasodilators, such as nitric oxide (NO) and prostacyclin, are decreased and endothelial vasoconstrictors, such as endothelin-1, are overproduced. As these affect not only vascular tone but also promote vascular remodeling, they represent promising targets for pharmacological treatments (Figure 1 ). Over the years, prostacyclin analog, endothelin receptor antagonists, and more recently phosphodiesterase type-5 inhibitor (PDE5), increasing NO, became available for PAH treatment. Several drugs targeting other physiopathological pathways are under investigation: tyrosin kinase inhibitors, Rho kinase inhibitors, statins, vasoactive intestinal peptide, serotonin recapture inhibitor, adrenomedulline. This review details hereafter the various therapeutic options available as well as the innovations under development.
Conventional treatment

General measures
Peripheral vasodilatation or increased cardiac demand will put PAH patient at risk of acute cardiac failure and syncope. For example, hot baths should be avoided and patients are advised to be precautious on hot days. Also, we traditionally advise against physical activity. Patients are taught to stay active while adapting effort according to their symptoms. Nevertheless, the appropriate level of physical activity is difficult to define as too much rest also has its attendant risks, physical deconditioning leading to worsened symptoms. To date, only one study has evaluated the effect of cardio-respiratory readaptation training in PAH. The program involved three weeks of inpatient rehabilitation followed by twelve weeks training at home with phone call supervision. No modification on cardiac hemodynamic was observed on echocardiography but 6-min walk test and quality of life were improved. More data are needed in order to recommend readaptation and studies are ongoing.
Altitude and hypoxia
As hypoxic vasoconstriction is an aggravating factor in PAH, stays at an altitude above 800 m and air flight in unpressurized cabin must be not recommended.
Chronic hypoxia (PaO 2 560 mmHg) warrants oxygen therapy for symptomatic purposes as well as to avoid PAH deterioration. Nevertheless, it is useful in the event of true shunt is debatable. In such cases, oxygen therapy upon effort could be considered.
Pregnancy and contraception
Pregnancy is formally contraindicated for PAH women. The hemodynamic and hormonal modifications occurring during pregnancy and peripartum period can lead to severe, and sometimes fatal, right heart failure [Bonnin et al. 2005; Sitbon et al. 2002b] . Consequently, contraception is strongly recommended in PAH women of childbearing age [Bonnin et al. 2005; Sitbon et al. 2002b] . Combined estrogen-progestin oral contraceptive is theoretically contraindicated, as their prothrombotic activity increases the risk of pulmonary embolism, which would worsen PAH [Kleiger et al. 1976] . Mechanical contraception (intra-uterine device) or surgical sterilization are typically recommended.
Anaesthesia and surgery
Hypotension is a common side-effect seen with the use of sedative and anaesthetic drugs. This is generally poorly tolerated by PAH patients, to the extent of being potentially life threatening. If hemodynamic instability occurs, it will be more difficult to manage in such patients and can rapidly be out of control. Consequently, it is recommended in general with PAH patients to avoid the use of sedatives as much as possible and to conduct any necessary surgery at centers specialized in the treatment of PAH, in order to coordinate surgical and medical interventions.
Contra-indicated drugs
Sympathomimetic drugs, often used in cold medication to relieve nasal congestion, are vasoconstrictors, and therefore should be avoided in PAH patients.
Beta-blockers, often use for cardiac comorbidities or esophageal variceal's prevention, counteract chronotropic response. This has been shown to be deleterious to PAH patients because it is a very important adaptative physiologic response that allows preservation of adequate cardiac output. To discontinue such drug in a PAH patient may lead, by itself, to important clinical and [Bjornsson and Edwards, 1985; Fuster et al. 1984] . As a result, anticoagulant therapy has become part of conventional therapy in PAH. Nevertheless, few studies actually support anticoagulation treatment in PAH; those that do are mostly retrospective or nonrandomized and generally include small number of patients with idiopathic PAH, actually support anticoagulation treatment in PAH [Rich et al. 1992; Fuster et al. 1984] . Current recommendations propose oral anticoagulation aiming for targeting an International Normalized Ratio (INR) between 1.5 and 2.5. Close INR monitoring is suggested when introducing endothelin receptor inhibitors and phosphodiesterase inhibitors because of drug interaction.
Although the somewhat sparse evidences base is derived exclusively from idiopathic PAH population, anticoagulation has been generalized to all patient groups, given the absence of contraindication. Special care in the application of anticoagulation is required with the hepatopulmonary PAH population because of the risk of esophageal variceal hemorrhage. Variceal ligation is a preventive option in these cases.
Diuretics
Right ventricular overload is part of PAH clinical presentation and has been identified as a negative prognostic factors [Sitbon et al. 2002a ]. Diuretics and salt-free diet relieve hypervolemia and associated symptoms. Whether this strategy improves prognosis is unknown. Furthermore, careful dosage adjustment is needed, based on clinical and hemodynamic findings, because hypovolemia can lead to a reduction in the right ventricular preload and decrease cardiac output [Naeije and Vachiery, 2001] .
Digitalization
Digoxin has been suggested as part of PAH therapy in the past because it produce an acute increase in cardiac output ]. Its long-term effectiveness is, however, dubious. Therefore, it is now reserved for some cases of PAH associated to auricular fibrillation ].
Specific PAH therapies
Calcium channel blockers Calcium channel blockers are vasodilatators and were initially introduced as part of PAH therapy to counteract vasoconstriction. Vasoconstriction has traditionally been assumed to be a preponderant mechanism in PAH. This is in some measure supported by pathological examination which had shown muscular hypertrophy and hyperplasia of the media of pulmonary arteries in PAH patients. Furthermore, vasodilatation challenge test with inhaled nitric oxide (NO) reveals partial release of vascular resistance. Also, Raynaud's syndrome is found in 10-14% of idiopathic PAH patients [Brenot, 1994; Rich et al. 1987 ], suggesting abnormal vasoconstriction response of systemic and pulmonary vessels [Fahey et al. 1984] . Historically, many vasodilators treatments were proposed in PAH (phentolamine, diazoxide, hydralazine, isoproterenol, angotensin-converting enzyme inhibitors) with debatable results [Reeves et al. 1986; Hughes and Rubin, 1986; Packer, 1985b; Mcgoon and Vlietstra, 1984; Packer et al. 1982; Rubin and Peter, 1980] . Only calcium channel blockers have been proven effective in rare carefully selected patients Rich et al. 1992; Packer, 1985a] . Thus, at the beginning of the 1990s, Rich et al. [1992] showed in an open prospective study that high dose of calcium channel blockers (nifedipine 90-240 mg/day or diltiazem 360-900 mg/day) significantly improve prognosis in patients with a positive vasodilatation response to acute testing. However, subsequently Sitbon et al. showed that only 12.6% of the 557 patients evaluated in our center could be treated by calcium channel blockers according to criterias established by Rich et al. [1992] . Moreover, only half of them maintained actual long-term benefit defined as NYHA functional class I or II at one year without the need for another treatment . In this study, a drop of mean pulmonary arterial pressure (mPAP) by at least 10 mmHg to reach a value lower than 40 mmHg, with a stable or increased cardiac output, during acute vasoreactivity testing was predictive of long-term response to calcium channel blockers. Vasodilators, in particular calcium channel blockers used at high dosages, must be avoided in the absence of proven significant vasoreactivity because of the risk of significantly reduced cardiac output and systemic blood pressure without reduction of pulmonary vascular resistances (PVR) . At the moment, mainly nifedipine and diltiazem are used, at higher dosages than those used in other indications [Rich et al. 1992 ]. The long-term effects of lower dosages were never evaluated. Verapamil is not recommended because of negative inotrope effects [Packer et al. 1984 ] and long-term effect of amlodipine was never evaluated [Woodmansey et al. 1996 ]. The side-effects most frequently observed with the calcium channel blockers are systemic hypotension and lower limb edema [Sitbon et al. 1998 ]. Prescription of low-dose diuretics and elastic socks will help reverse those side-effects.
Prostacyclin agonist
Prostacyclin (prostaglandin-I 2 ) is an arachidonic acid by-product produced by the endothelial cells and has a very short half-life of 3 min [Moncada et al. 1976 ]. It is a powerful systemic and pulmonary vasodilator as well as a powerful platelet aggregation inhibitor through the increase in intracellular cyclic adenosine monophosphate (AMPc) [Rubin et al. 1990; Moncada et al. 1976 ]. Moreover, prostacyclin seems to play an important role as antiproliferative, cytoprotector, and fibrinolytic and it reduces leucocytes marginalization and adherence [Jones, 1996] .
Epoprostenol: Intravenous epoprostenol has been used in the treatment of PAH since the 1980s in a research context and has appeared on European registry since 1997 [Higenbottam et al. 1984] . Acute vasodilatation response is not a predictor of long-term response to epoprostenol [Mclaughlin et al. 1998 ], suggesting that epoprostenol also serves to counteract vascular remodeling [Castelain et al. 2002; Rubin et al. 1990; Mclaughlin et al. 1998 ].
A randomized trial showed the effectiveness of the epoprostenol among 81 patients suffering from idiopathic HTAP in NYHA functional class III and IV [Barst et al. 1996] . After twelve weeks of treatment, a significant improvement of functional class, distance covered during the 6-min walk distance test (6MWD) as well as hemodynamic improvement was observed in the epoprostenol group. Moreover, a significant improvement of survival was observed (no death at twelve weeks in the group treated with epoprostenol against eight deaths in the conventional group). It is to this day the only prospective study having shown an effect on short-term survival (twelve weeks). Long-term effectiveness has never been evaluated prospectively but retrospective analysis comparing patients treated by IV epoprostenol with data from patients treated with conventional therapy find meaningful clinical benefit for patients in NYHA functional class III or IV [Kuhn et al. 2003; Mclaughlin et al. 2002 Mclaughlin et al. , 1998 Sitbon et al. 2002a; Shapiro et al. 1997 ]. Functional class, hemodynamic parameters, and long-term survival were all improved in the group treated with IV epoprostenol. The hemodynamic benefits were maintained at one year. Survival rates at one, two, three, and five years were 85, 70, 63, and 55%, respectively, compared to 58, 43, 33, and 28% in the control group (p50.0001) [Sitbon et al. 2002a ]. The clinical and hemodynamic response to treatment were other important prognostic factors. Improvement of functional class after treatment with epoprostenol, walking more than 380 m on the 6MWD, and total pulmonary resistance decrease by 30% or more were predictive of a significantly better survival Sitbon et al. 2002a ].
Epoprostenol had initially been proposed as a bridge-therapy for lung transplantation but it is currently regarded as the treatment of reference for severe PAH and represents a true alternative to transplantation. Data collected in 19 centers in the United States showed that two-thirds of the patients treated by epoprostenol improved sufficiently to avoid the necessity of lung transplantation [Robbins et al. 1998 ]. However, the patients who are still in NYHA functional class III or IV after three months of treatment have a poor prognosis and should be on the transplantation list [Sitbon et al. 2002a ].
Epoprostenol, like endogenous prostacyclin, has a short half-life of about 3 min and thus needs to be administered by continuous IV perfusion through tunnelized catheter. Hospitalization is needed to install the catheter, to begin and monitor therapy and to educate patient on manipulations and strict asepsis [Sitbon et al. 2002b ]. Epoprostenol is started at low dose of 1 ng/kg/mn and is gradually increased by 1 ng/kg/mn every 12 h up to 10 ng/kg/ mn during a short hospitalization [Sitbon et al. 2002b] . Thereafter, dosage is increased every two weeks up to a long-term doses range of 22-45 ng/kg/mn depending on the balance between improvement and side-effects.
In spite of clear benefit, epoprostenol perfusion cannot be considered an ideal treatment. It is complex, uncomfortable, and expensive. Sideeffects are frequent: jaw pain, headache, diarrheas, flushes, lower limbs pain, nausea, and vomiting [Sitbon et al. 2002b; Mclaughlin et al. 2002; Robbins et al. 1998; Barst et al. 1996 ]. These side-effects are dose-dependent and generally of moderate intensity, not requiring interruption of treatment. Severe pulmonary edema can occur during the treatment by epoprostenol, especially in patients with veno-occlusive disease and pulmonary capillary hemangiomatosis Rubin, 1997] . The most severe complications are related to the mode of administration. The incidence of thrombosis and infections is 0.1-0.6 cases annually per patient Sitbon et al. 2002a; Mclaughlin et al. 1998 ]. Treatment interruption secondary to pump dysfunction or the rupture of the catheter, although rare, can potentially be fatal [Sitbon et al. 2002b] .
Other stable prostacyclin analogs
The complications related to central venous catheter used for the intravenous administration of epoprostenol have lead to the development of other prostacyclin agonist with different delivery mode (subcutaneous, inhaled, or oral).
Treprostinil: Treprostinil is a prostacyclin analog which benefits from a longer half-life of 58-83 min by subcutaneous (S/C) administration [Laliberte et al. 2004] . It is delivered by a minipump similar to those used for insulin . Subcutaneous treprostinil has been approved since 2005 in France. A multicentric-randomized trial evaluated treprostinil S/C vs placebo over twelve weeks in 470 patients in NYHA functional class II-IV suffering from idiopathic PAH, PAH related to a congenital cardiopathy with a shunt, or PAH associated with a connective tissue disease . A modest but statistically significant improvement of the 6MWD was observed (þ16 m) on the total population. The dyspnea score and hemodynamic parameters were also significantly improved. The impact was dose-related but side-effects often prevented optimal dosing. The highest dose was 22.5 ng/kg/ min. Local side-effects such as pain and inflammation at the injection site were very frequent (485% of the cases) and lead to treatment cessation in 8% of the cases . Two studies evaluated long-term effect of subcutaneous treprostinil [Barst et al. 2006a; Lang et al. 2006 ]. Long-term follow-up in a retrospective study showed that among 860 patients in NYHA functional class III-IV and treated by treprostinil S/C over a four-year period, only 38% of the patients remained on treprostinil monotherapy [Lang et al. 2006 ]. The survival rate were 87, 78, 71, and 68% at one, two, three, and four years respectively, significantly higher than predicted survival of 69, 56, 46, and 38 from NIH equation [D'alonzo et al. 1991] . Another long-term followup retrospective study involving 122 patients showed similar results on survival but the event free survival, including monotherapy, was 69% at three years [Lang et al. 2006 ]. However, to date, no prospective study has demonstrated such outcome, neither in comparison to placebo nor to other treatment used in PAH.
Treprostinil longer half-life prolonges drug preparation intervals to 48-96 h compare to 12 h for epoprostenol. The study from Simonneau et al. [2002] showed that 24% of patients experienced pump dysfunction but none lead to serious clinical consequences. More importantly, the longer halflife decreases the risks of clinical deterioration in the event of accidental interruption of the perfusion [Sitbon et al. 2007; Rubenfire et al. 2007; Tapson et al. 2006; Gomberg-Maitland et al. 2005a ]. Trepostinil had also been shown to be an alternative that can be used transiently, without risk of deterioration, in the event of serious catheter infection complications with IV epoprostenol . Treprostinil is usually given through S/C route but it is also available intravenously [Sitbon et al. 2007; Rubenfire et al. 2007; Gomberg-Maitland et al. 2005a; Tapson et al. 2006 ]. Lastly, inhalation delivery (TRIUMPH study) and oral administration are currently under investigation [Voswinckel et al. 2006 ].
Iloprost: Iloprost is a prostacyclin analog that is administered by inhalation and was approved by the European authorities (EMEA) in idiopathic PAH (iPAH) with NYHA functional class III in 2003 [Olschewski et al. 2000; Hoeper et al. 2000 ]. Nevertheless, its short half-life is an important drawback. Six to nine inhalations a day are needed and each of them requires approximately 30 min [Hoeper et al. 2000; Olschewski et al. 2002 ]. An open monocentric study showed promising results in 24 patients with iPAH in NYHA functional class III-IV, both on the 6MWD and the hemodynamic parameters at three months and one year [Hoeper et al. 2000 ]. However, some patients reported an increase in their symptoms between inhalations. The only randomized multicentric study involving 203 patients with idiopathic and chronic thromboembolic PAH in NYHA functional class III-IV showed that although post inhalation hemodynamic parameters do improve after twelve weeks of treatment with iloprost, there is no significant modification in measurements made pre inhalation. On the other hand, the hemodynamic parameters in placebo group showed deterioration. The 6MWD improved by 36 m in iloprost group compared to placebo. The gain was even more pronounced in iPAH with an improvement of 59 m in the iloprost group compared to the placebo group. Nonetheless, only 17% of patients receiving iloprost reached the primary combine goal of 10% increase on the 6MWD and improvement in NYHA functional class against 4% in the placebo group with five events in the iloprost group and none in the placebo group .
Cough and symptoms related to vasodilatation represented the main reported side-effects . It is important to mention that in the study conducted by Olschewski et al. [2002] , the number of syncope was significantly more important in the group treated by iloprost.
Also, long-term data with the inhaled iloprost are unfortunately rather disappointing. In a retrospective study involving 76 patients on inhaled iloprost, only 6 patients remained under iloprost monotherapy during the follow-up, the other patients received an alternative treatment or a combination therapy (n ¼ 41), were transplanted (n ¼ 6), died (n ¼ 11), or stopped iloprost for another reason (n ¼ 12) [Opitz et al. 2005] . Survival rate without event was 53% to one year and 17% to four years. More importantly, survival rate was not different from the predicted survival with conventional therapy [D'alonzo et al. 1991] .
Beraprost: Beraprost is an oral prostacyclin agonist. Initially, open-label or retrospective studies showed encouraging results with the use of beraprost in PAH [Nagaya et al. 2002 [Nagaya et al. , 1999 Vizza et al. 2001] . A multicentric, double-blind placebo-controlled study was subsequently conducted by . This twelve-week study involved 130 patients in NYHA functional class II (50%) or III (50%), suffering from iPAH, PAH associated with collagen vascular disease, congenital systemic-to-pulmonary shunt, or HIV. Results indicated significant improvement on the 6MWD in the idiopathic PAH subgroup only. Beraprost treatment was not associated with hemodynamic improvement. Subsequently, Barst et al. [2003] conducted a one-year placebocontrolled study evaluating 116 patients with idiopathic PAH, in NYHA functional class II (50%) or III (50%), which yielded rather disappointing results in terms of disease progression (death, lung transplantation, requirement for IV epoprostenol, or a reduction of more than 25% of the peak VO2). Improved outcome with beraprost was only observed at six months; there was no difference at three, nine, and twelve months compared to placebo control. Similarly, the 6MWD was improved compared to placebo control at three and six months, but this initial improvement in scores was not maintained at nine and twelve months. These results suggest that initial efficacy attenuates with time and beraprost does not influence disease progression or prognosis, perhaps due to the tachyphylaxia phenomenon classically described with the prostaglandins. Systemic sideeffects observed with the beraprost limit the increase in dosage and may have contributed to its lack of efficacy. These results have precluded the marketing of beraprost.
Endothelin receptors antagonists
Endothelin-1 (ET-1) has been shown to play an important role in the pathogenesis of PAH. It is a powerful vasoconstrictor and a promoter of smooth muscle cell proliferation. High ET-1 plasma levels are found in patients suffering from PAH and are correlated with poor prognosis. There are two types of ET-1 receptors: ET-A and ET-B. Vasoconstriction is believed to be mediated by ET-A receptor activation, while ET-B agonists promote vascular smooth muscle proliferation.
Dual ET-1 receptors antagonist: Bosentan is a dual ET-1 receptors antagonist. It was the first oral treatment available for PAH patients and was approved in Europe in 2002. Two prospective randomized trials evaluated the efficacy of bosentan compared to placebo among patients with idiopathic PAH or PAH associated with connective tissue diseases, in functional class III-IV Channick et al. 2001] . Significant improvement was observed on NHYA functional class, 6MWD and hemodynamic parameters in the bosentan group. In contrast, each of these parameters reflected deterioration in the placebo group [Channick et al. 2001 ]. The treatment effect was 44 m on the 6MWD in the total study population and a gain of 52 m in the idiopathic PAH subgroup. More interestingly, time to clinical worsening, defined by death, lung transplantation, hospitalization for disease decompensation, atrioseptostomy, or the need for epoprostenol was improved in the bosentan group .
Open-label extension of these studies allowed long-term evaluation of patients and showed that the functional and hemodynamic improvements were maintained over time [Sitbon et al. 2003 ]. Another long-term follow-up study showed an improvement of survival with bosentan first-line therapy, as compared with predicted survival with conventional therapy [Provencher et al. 2006b; Mclaughlin et al. 2005; D'alonzo et al. 1991] . Overall survival was 90, 87, and 79% with the bosentan first-line treatment strategy compared with 71, 61, and 51% predicted by the NIH equation at one, two, and three years, respectively [Provencher et al. 2006b ]. On the other hand, survival without event (death, transplantation, need for another PAH treatment, hospitalization for right heart failure) was only 61, 44, and 40% at one, two, and three years, respectively. Twenty-three to fortyfour percent of the patients required the addition of a prostacyclin agonist (primarily intravenous epoprostenol) during the follow-up, depending on the attitude on intensity of treatment [Provencher et al. 2006b ].
The main side-effects are systemic vasodilatation and hepatic dysfunction. A dose-dependent rise in hepatic enzymes to more than three times normal occurred in 11% of the cases . Monitoring of hepatic enzyme levels is consequently indicated monthly when bosentan is employed; it is recommended to reduce bosentan dosage if the hepatic enzymes reach three times the normal limit and to discontinue its usage altogether if hepatic enzymes reach five times the normal limit.
Selective ET-A receptors antagonists: Selective ET-A receptors antagonists offer the theoretical advantage of blocking vasoconstriction induced by ET-1 on ET-A receptors on the muscular smooth cells, while preserving ET-1 activity on ET-B receptors, which is thought to be responsible for a vasodilatation and increase in ET-1 clearance .
Sitaxsentan is a selective ET-A receptors antagonist with an affinity 6500 times greater for ET-A than for ET-B. In the first prospective randomized study against placebo involving patients in functional class II and III suffering iPAH, PAH related to connective tissue disease or congenital heart disease , sitaxsentan improved hemodynamic parameters and performance on the 6MWD by 35 m . A post hoc analysis revealed the greatest benefit was observed in iPAH and PAH conditions related to connective tissue disease in functional class III (i.e., a 65 m increase in the 6MWD). However, sitaxsentan use did not produce improvement in peak-VO2, which was the primary goal of this study; nor did it delay time to clinical worsening (defined as death, epoprostenol use, atrial septostomy, or transplantation) at twelve weeks. Notably, a second randomized study involving similar populations, showed comparable results on 6MWT and NYHA; again, there was no difference in time to clinical worsening [Barst et al. 2006b ].
Only one study with a small population of patients (eleven patients) has been published on long-term efficacy and safety of sitaxsentan. In this study, initial gains were maintained after one year and no serious adverse effect were reported .
In terms of side-effect profile, in the first open study carried out among 20 patients, two cases of cytolytic hepatitises were observed on a regiment of 500 mg daily of sitaxsentan, one of which was fatal . Subsequent randomized studies involving sitaxsentan reported hepatic cytolyses in 10% of patients on 300 mg daily, none of which were fatal. No hepatic cytolyses were observed in patients on the 100 mg daily regiment.
Ambrisentan is another selective ET-A receptor antagonist and was evaluated in two controlled studies, of which only one has been published. Four dosages (1, 2.5, 5, 10 mg daily) were evaluated with 64 patients in functional class II-III, suffering from iPAH, PAH related to anorexigen, collagen vascular disease, or human immunodeficiency virus (HIV) [Galie et al. 2005a ]. After twelve weeks, the 6MWD was increased by 36 m and hemodynamic parameters were significantly improved; there was no dose-response effect. Twenty percent of patients experienced clinical worsening defined as death, all-cause hospitalizations, or need for other PAH therapeutic agents and diuretics, although the latter explained half of the cases, while the incidence of hepatic cytolysis was 3%. These results were reportedly confirmed in a study against placebo involving a larger number of patients (study ARIES 2, unpublished data).
Phosphodiesterase type-5 inhibitors
Phosphodiesterase type 3, 4, and 5 are the three main types of this enzyme found in pulmonary artery contractive cells. PDE-5 specifically contributes to cyclic guanosine monophosphate (GMPc) breakdown, thus decreasing smooth muscle cell capacity for vasodilatation while promoting proliferation. Several experimental works showed a beneficial effect of PDE-5 inhibitors on vascular remodeling and vasodilatation [Schermuly et al. 2004; Ghofrani et al. 2002] .
Sildenafil is an oral PDE-5 inhibitor that is now available for idiopathic PAH in Europe since 2005.
Therapeutic Advances in Respiratory Disease
A recent randomized, placebo-controlled study evaluated the twelve-week efficacy of sildenafil 20, 40, or 80 mg three time daily among 278 patients with idiopathic PAH, PAH associated with connective-tissue disease, or with repaired congenital cardiopathy, in NYHA functional class II-III [Galie et al., 2005b] . Results indicated that the 6MWD was improved by 50 m; furthermore, significant hemodynamic and functional class improvements were seen in every sildenafil group. No statistical difference in the time to clinical worsening or in the incidence of clinical worsening was observed with sildenafil as compared to placebo [Galie et al. 2005b ]. Among the 222 patients who continued sildenafil monotherapy as part of a long-term extension study, all patients on 80 mg three times daily, the gain in 6MWD was maintained. However, sildenafil' approval in Europe is currently limited to 20 mg three times daily. No data is currently available on the longterm efficacy of this lower dosage.
Minor side-effects like flushes and digestive disorders were reported. No elevation in hepatic enzymes was noted.
Other PDE-5 inhibitors, namely tadalafil and vardenafil, are under evaluation in PAH.
Combined therapy
Another therapeutic option is to combine drugs with different mechanisms of action, in order to optimize clinical benefit while minimizing sideeffects. The two possible tactics of combined therapy are either to add a new medication to an ongoing treatment yielding suboptimal results (sequential combination) or in first intention by starting from the beginning with a combination treatment . Only one controlled trial evaluated the efficacy of first intention combined therapy in comparison to monotherapy . The BREATHE-2 trial compared the association of IV epoprostenol and oral bosentan with IV epoprostenol and placebo among 33 patients with severe PAH over a twelveweek period ]. Reduction in PVR was greater with combination therapy (TPR reduced by 59% compared to 45% with monotherapy), although it did not reached statistical significance ( p ¼ 0.08). Furthermore, no benefit could be shown on the 6MWD with combination therapy compared to epoprostenol alone (þ68 m and þ74 m, respectively). These results, however, may be related to the small number of patients and the short-term follow-up in the context of the addition of a treatment to a drug already known to bring an important benefit in severe PAH patients. In a recent controlled trial, the sequential addition of oral sildenafil 80 mg three times daily for patients already receiving IV epoprostenol with insufficient improvement, proved to be more effective than the placebo on the 6MWD and hemodynamic parameters. More importantly, there was a significant reduction in the number of patients showing clinical worsening and an improvement of survival among most severe patients [Simonneau, 2007] . There is currently no data on the addition of bosentan in such context. Only one randomized, placebo-controlled study has looked at the effect of sequential combination therapy to bosentan yielding suboptimal results. The combination of iloprost to bosentan in patients with iPAH or associated PAH in NYHA functional class III was shown to be significantly better than placebo and bosentan in terms of 6MWD (þ26 m), NYHA functional class and on post inhalation hemodynamic parameters (PVR -26.4%) ]. Several uncontrolled studies evaluated the efficacy of other associations with encouraging results. The open-label sequential addition of bosentan or sildenafil to epoprostenol, treprostinil or iloprost was shown to be of interest [Gomberg-Maitland et al. 2005b; Kataoka et al. 2005; Ghofrani et al. 2003; Hoeper et al. 2003 ]. Also, the association of bosentan and sildenafil, both available in oral form, offers an interesting option [Mathai et al. 2007; Hoeper et al. 2004 ]. However, there are pharmacological interactions between these drugs. Bosentan accelerates sildenafil metabolism, maybe altering its efficacy, and sildenafil increases bosentan plasmatic concentrations, and thus the risk of hepatotoxicity [Paul et al. 2005] . Although the clinical significance of these interactions still requires clarification, bosentan post commercialization surveillance has not revealed an increase in the incidence of hepatotoxicity.
Currently, the limited data precludes consensus on which combined treatment or strategy should be preferred. Also, no long-term evaluation of combination therapy is available. Combination therapy is certainly an interesting approach that must be further studied in order to guide therapeutic choices.
Potential future therapies
Tyrosine kinase inhibitors One of the most promising agents currently debated in PAH is platelet-derived growth factor (PDGF) inhibitors, such as imatinib mesylate. PDGF has been implicated in endothelial cell dysfunction and proliferation and migration of smooth muscle cells. It has been suggested that PDGF may play a role in PAH [Perros et al. 2008; Barst, 2005; Panos and Baker, 1996] . Hydrogen peroxide induces the expression of PDGF in the human pulmonary endothelial cells, as does hypoxia or shear stress. Recently, pulmonary vascular remodeling in two animal models of PAH was shown to regress with the administration of imatinib mesylate (Gleevec Õ ), a PDGF receptors antagonist approved for the treatment of chronic myeloid leukemia [Schermuly et al. 2005] . Moreover, case reports suggest a beneficial effect of imatinib among severe PAH patients [Patterson et al. 2006; Souza et al. 2006; Ghofrani et al. 2005 ]. However, possible cardiac adverse effects on long-term use might limit its benefice [Kerkela et al. 2006 ].
Rho kinase inhibitors
RhoA protein is one of the best known members of the Rho proteins family. It controls a great number of fundamental cellular functions like contraction, migration, proliferation, and apoptosis. RhoA acts through the proteinkinases Rho (RhoKs) activation. In vitro culture of endothelial human cells have shown that the reduction in endothelial NO synthetase expression secondary to hypoxia is mediated by RhoKs. Finally, several studies showed that the activation of the RhoA/ RhoKs pathway contributes to vasoconstriction and vascular remodeling [Guilluy et al., 2005; Nagaoka et al. 2005] . RhoKs inhibitor, fasudil, reduces vasoconstriction induced by acute hypoxia and prevents the development of vascular remodeling and chronic hypoxic PAH [Fagan et al. 2004] . Ishikura et al. [2006] have tested the short-term effect of intravenous fasudil on hemodynamics during right heart catheterization in eight patients with severe PAH. Intravenous fasudil significantly decreased mPAP and total pulmonary resistance (TPR) while it increased cardiac index (CI) [Ishikura et al. 2006 ]. These results suggest that RhoKs inhibitor could be a novel therapeutic agent against PAH. Moreover, the RhoA/RhoKs pathway inhibition is thought to be involved in sildenafil effects in PAH.
It was shown that sildenafil increases RhoA phosphorylation, which promotes binding to guanine dissociation inhibitor (GDI), an inhibiting cytosolic protein, in the pulmonary arteries [Guilluy et al. 2005] .
Statins (HMG-CoA reductase inhibitors)
In animal models, simvastatin was proven to have antiproliferative and pro-apoptotic effect on smooth muscle cells, resulting in the prevention of pulmonary vascular remodeling [Nishimura et al. 2002; Girgis et al. 2003 ]. Moreover, simvastatin preclude intimal neo-formation in PAH animal models [Nishimura et al. 2003 ]. A recent study has shown that simvastatin enhances bone morphogenetic receptor II (BMPR-II) expression in pulmonary artery smooth muscle cells and endothelial cells [Hu et al. 2006 ]. BMPR-II mutations are known to be involved in familial PAH. An open-label observational study involving 16 patients with PAH suggested that statins were safe and improved the 6MWD [Kao, 2005] . However, there is currently no randomized control trial confirming statins' efficacy in humans with PAH.
Vasoactive intestinal peptide
Vasoactive intestinal peptide (VIP) is a neuropeptide, which acts mainly like a neuro-transmitter and activates AMPc and GMPc. It is a potent bronchodilatator and a systemic and pulmonary vasodilator. It also inhibits the smooth muscle cell proliferation and decreases platelets aggregation. Low serum concentrations and decreased VIP immunoreactivity were shown in pulmonary arteries of patients with PAH [Petkov et al. 2003 ]. Also, VIP gene depletion in mice produces a moderate pulmonary hypertension with medial hypertrophy of small pulmonary arteries, increased mPAP, and right ventricle hypertrophy [Said et al., 2007] . Inhaled VIP (four inhalations daily) was shown to improve clinical and hemodynamic parameters after three months of treatment in eight patients with PAH. No adverse effects were reported [Petkov et al. 2003 ]. Further studies are needed to confirm these results.
Selective serotonin-reuptake inhibitors Serotonin (5-hydroxytryptamine, 5HT) has vasoconstrictive and mitogenic properties. High plasmatic serotonin concentrations were found in patients with PAH [Herve et al. 1995] . However, the mechanism of action of serotonin is complex and its role in the PAH physiopathology is not yet clearly defined. Selective serotonin-reuptake inhibitors were shown to have a protective effect on the occurrence of PAH in animal models [Marcos et al. 2003 ]. Studies are on going to determine the potential efficacy of this therapeutic class in the human with PAH.
Adrenomedullin
Adrenomedullin is a vasodilatator peptide and a smooth muscle cell proliferation inhibitor in pulmonary vasculature in vitro [Nagaya et al. 2004; Upton et al. 2001] . Intravenous or inhaled adrenomedullin decreases PVR in patients with idiopathic PAH [Nagaya et al. 2004 [Nagaya et al. , 2003 Kandler et al. 2003 ]. Nevertheless further evaluation is needed.
Nonmedical treatment
Atrioseptostomy
Atrioseptostomy consists in creating an interauricular communication. The objective is to decrease the right heart volume, subjected to a high after load secondary to increased pulmonary resistances [Sandoval et al. 2001 ]. Symptoms and prognosis in PAH are directly influenced by the severity of right heart failure [Gaine and Rubin, 1998; D'alonzo et al. 1991] . Also, the presence of a right-left shunt, secondary to congenital cardiac malformation or a patent foramen oval, among patients with severe HTAP seems to carry a better prognosis [Mclaughlin et al. 2004; Roskovec et al. 1986 ]. The surgical creation of a right-left shunt decreases right auricular pressure, increases systemic blood flow, and later on, leads to a reduction in the right ventricle tension [Sandoval et al. 2001] . Thus, in spite of arterial desaturation induced by the shunt, oxygen delivery is improved [Sandoval et al. 2001] .
Atrioseptostomy have never been studied in controlled clinical trials. However, several experienced teams reported their data and it seems that immediate mortality is high, reaching 14% during the first week, particularly in the case of severe desaturation and right heart failure [Kerstein et al. 1995; Rich et al. 1997; Rothman et al. 1999; Sandoval et al. 2001 Sandoval et al. , 1998 Rich and Lam, 1983] . Among surviving patients, the improvement of symptoms and of functional capacity are undeniable. Atrioseptostomy constitutes an alternative for severe PAH patients waiting for lung transplantation and worsening despite maximum medical treatment [Rothman et al. 1999] . In all cases, atrioseptostomy should only be carried out in centers with an important experience, both with atrioseptostomy and with patients with PAH.
Lung transplantation
Lung transplantation was historically the treatment of choice for severe PAH and still is if medical treatments are insufficient [Sitbon et al. 2002a, b] . However, this particularly extensive surgery can be proposed only to a minority of patients suffering from PAH. Moreover, longterm benefits remain disappointing with 50% survival at five years [Hosenpud et al. 2001 ]. Early mortality is mainly related to infectious complications whereas late mortality reflects mostly chronic rejection (obliterating bronchiolitis). One-lung transplantation had good longterm results [Pielsticker et al. 2001; Levine et al. 1990 ] but most centers currently prefer two-lung transplantation, which has less postoperative complications [Mendeloff et al. 2002] . Cardiopulmonary transplantation may be necessary for patients presenting with terminal right heart failure or complex congenital cardiopathy [Reitz et al. 1982 ].
Treatment algorithm
Although numerous studies are now available, it is still not established which drug should be introduced first or which and when combination therapy should be used. Moreover, while many parameters have been shown to predict prognosis, there is no consensus on what are the most relevant end points to guide therapy. Expert consensus have drawn general management algorithm. The choice of optimal treatment will be dictated by clinical experience and drug availability, as well as patient preference. Figure 2 indicates the current PAH management at the South Paris University Pulmonary Vascular Center. There is a substantial need for randomized controlled trial and long-term observational studies evaluating the different treatments in terms of survival, time to clinical worsening, quality of life, side-effects, and costs.
Conclusion
In conclusion, advances in medical treatment options for PAH have allowed improvement in patients' functional class, exercise capacity, hemodynamic parameters, time to clinical worsening, and even survival. Future studies are necessary in order to clarify treatment strategy such as combination therapy, treatment for less severe patients, or specific PAH subpopulations. We are still in need of a curative therapy. Fortunately, active research is ongoing.
Pulmonary arterial hypertension (functional class II/III/IV NYHA) Figure 2 . Treatment algorithm in pulmonary arterial hypertension 1. This algorithm is fairly accepted for patients in NYHA functional class III or IV, whereas data for patients in functional class II are less comprehensive. Treatments were primarily evaluated in the idiopathic PAH, and PAH associated with scleroderma or anorexigen. Extrapolation of this algorithm to the other PAH etiology must thus be carried out with caution. 2. Vasoreactivity testing should be carried out with short half-life agents such as inhaled NO, IV prostacycline or IV adenosine. Long-term calcium channel blockers treatment should be proposed only to 'responders', defined as patients with a drop in mPAP of more than 10 mmHg to reach a value lower than 40 mmHg, in association with stable or increased cardiac output. 3. The majority of experts recommend treating patients in NYHA functional class IV by IV epoprostenol. For all the other situations, no specific first line therapy can be recommended over another based on literature. See country-specific regulatory agency approval status and functional class indications for PAH. 4. Few studies showed benefits in functional class II patients. Prevention of clinical worsening can be considered an important goal in mildly symptomatic PAH patients. Risk and benefits should be discussed with patients. See also country-specific regulatory agency approval status for functional class II patients. 5. Combination therapy is an option to consider when patients remain in NYHA functional class III or IV after first line monotherapy. Nevertheless, more studies are necessary to confirm the interest of such strategy. 6. Pulmonary transplantation represents an alternative for potentially operable patients who remain in functional class III or IV of the NYHA after three months of treatment by IV epoprostenol. It is essential to take into account the relatively long waiting list for transplantation in the decision. Atrioseptostomy is an alternative for patients having severe PAH which worsens in spite of a maximum medical treatment.
